Multi-gene Signature of Microcalcification and Risk Prediction among Taiwanese Breast Cancer

Hsin-Tien Tsai, Ching-Shui Huang, Chao-Chiang Tu, Chih-Yi Liu, Chi-Jung Huang, Yuan-Soon Ho, Shih-Hsin Tu, Ling-Ming Tseng, Chi-Cheng Huang Multi-gene Signature of Microcalcification and Risk Prediction among Taiwanese Breast Cancer

Supplementary information

Supplementary Figure legends

Supplementary Fig 1 Relapse-free survival of Taiwanese breast cancers stratified by PAM50 molecular subtypes. Only subjects with long-term follow up were surveyed. SSP2: single sample predictor without normal breast-like subtype; Basal: basal-like; HER2: HER2-enriched; Lum-A: luminal A; Lum-B: luminal B molecular subtype; X-axis: survival time in year.

Supplementary Fig 2 Volcano plot of Taiwanese breast cancer transcriptome. Blue dots indicated genes with differential mRNA abundance pertaining pathological microcalcification (p-value <0.001).

Supplementary Fig 3 Volcano plot of Taiwanese breast cancer transcriptome. Blue dots indicated genes with differential mRNA abundance pertaining coexistent DCIS (p-value <0.001).

Supplementary Fig 4 Cross-validated Receiver Operating Characteristic (ROC) curve of Bayesian compound covariate predictor (BCCP) classifier for multi-gene signature pertaining microcalcification.

Supplementary Fig 5 Boxplots of microcalcification-relevant genes in independent dataset (GSE2109). Each plot includes mRNA abundance for one gene stratified by the class variable in X-axis (0: without microcalcification and 1: with microcalcification). The Y-axis represents log intensity and the title shows gene symbol. All comparisons were insignificant with p-values >0.001 (Wilcoxon rank sum test).

Gene symbol list (from top to bottom) for Y-axis of Fig 3



Supplementary Fig 1



Supplementary Fig 2



Supplementary Fig 3



Supplementary Fig 4





















Supplementary Fig 5

Probe set	Description	Symbol
202431_s_at	v-myc avian myelocytomatosis viral oncogene homolog	MYC [1]
205067_at	interleukin 1, beta	IL1B [2]
205205_at	v-rel avian reticuloendotheliosis viral oncogene homolog B	RELB [1]
206036_s_at	v-rel avian reticuloendotheliosis viral oncogene homolog	REL [1]
207535_s_at	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)	NFKB2 [1]
209189_at	FBJ murine osteosarcoma viral oncogene homolog	FOS [1]
209239_at	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	NFKB1 [1]
209875_s_at	secreted phosphoprotein 1	SPP1 [3,4]
209878_s_at	v-rel avian reticuloendotheliosis viral oncogene homolog A	RELA[1]
212667_at	secreted protein, acidic, cysteine-rich (osteonectin)	SPARC [4]
236028_at	integrin-binding sialoprotein	IBSP [4-7]
208378_x_at	fibroblast growth factor 5	FGF5 [8]
209101_at	connective tissue growth factor	CTGF [8]
209201_x_at	chemokine (C-X-C motif) receptor 4	CXCR4 [8]
206924_at	interleukin 11	IL11 [8]
204475_at	matrix metallopeptidase 1	MMP1 [2,9]

Supplementary Table 1. Candidates of microcalcification-relevant genes from literature reviews.

References to Supplementary Table 1

- McCarthy GM, Augustine JA, Baldwin AS, Christopherson PA, Cheung HS, Westfall PR, Scheinman RI (1998) Molecular mechanism of basic calcium phosphate crystal-induced activation of human fibroblasts. Role of nuclear factor kappab, activator protein 1, and protein kinase c. J Biol Chem. 273:35161-9.
- Rutter JL, Benbow U, Coon CI, Brinckerhoff CE (1997) Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem 66:322-36.
- Scimeca M, Giannini E, Antonacci C, Pistolese CA, Spagnoli LG, Bonanno E (2014) Microcalcifications in breast cancer: an active phenomenon mediated by epithelial cells with mesenchymal characteristics. BMC Cancer 14:286.
- Bellahcène A, Bachelier R, Detry C, Lidereau R, Cl?zardin P, Castronovo V (2007) Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 101:135-48.
- 5. Bellahcène A, Merville MP, Castronovo V (1994) Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54:2823-6.
- Bellahcène A, Castronovo V (1995) Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146:95-100.Bellahc?ne A, Kroll M, Liebens

F, Castronovo V (1996) Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11:665-70.

- Bellahcène A, Kroll M, Liebens F, Castronovo V (1996) Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11:665-70.
- Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cord?n-Cardo C, Guise TA, Massaguè J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-49.
- Morgan MP, Cooke MM, Christopherson PA, Westfall PR, McCarthy GM (2001) Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines. Mol Carcinog 32:111-7.

Supplementary Table 2. Intersect of differentially expressed genes pertaining microcalcification and DCIS.

Probe set	Description	Symbol
1552845_at	claudin 15	CLDN15
1559050_at	HLA complex group 27 (non-protein coding)	HCG27
1560112_at	WD repeat and FYVE domain containing 2	WDFY2
1569315_s_at	long intergenic non-protein coding RNA 894	LINC00894
1569320_at	GC-rich promoter binding protein 1-like 1	GPBP1L1
1569484_s_at	MDN1, midasin homolog (yeast)	MDN1
207287_at	BIN3 intronic transcript 1 (non-protein coding)	BIN3-IT1
207987_s_at	gonadotropin-releasing hormone 1 (luteinizing-releasing hormone)	GNRH1
215203_at	golgin A4	GOLGA4
217671_at	Down syndrome encephalopathy related protein 1	DSERG1
218246_at	mitochondrial E3 ubiquitin protein ligase 1	MUL1
232804_at	uncharacterized LOC100506385	AP000330.8
236320_at	coiled-coil domain containing 17	CCDC17
237783_at	PLAC8-like 1	PLAC8L1
238412_at	RNA polymerase I transcription factor homolog (S. cerevisiae) pseudogene 3	RRN3P3
239556_at	uncharacterized LOC645513	LOC645513
240868_at	uncharacterized LOC100129406	LOC100129406
244840_x_at	dedicator of cytokinesis 4	DOCK4

Microarray											
experiment	DCIS	Comed-DCIS	Microcalcification	Survival time(year)	Relapse status	ER	PR	Grade	HER2 IHC(ISH)	HER2 status	Predicted risk group
names											
7 cancer.CEL	0		0	5.58	0	80	10	3	2	0	low
8 cancer.CEL	1	1	1	1.58	1	0	0	3	3	1	low
9 cancer.CEL	0		0	5.75	0	85	50	2	1	0	low
10 cancer.CEL	1	0	1	5.50	0	80	50	1	1	0	high
12 cancer.CEL	1	0	1	5.67	0	90	0	1	2	0	low
13 cancer.CEL	1	1	1	2.08	1	0	0	3	2	0	high
14 cancer.CEL	1	1	1	5.58	0	0	0	2	3	1	low
15 cancer.CEL	1	1	1	5.50	0	70	20	3	3	1	low
22 cancer.CEL	1	0	0	5.58	0	0	0	3	1	0	high
23 cancer.CEL	0		0	5.67	0	80	90	2	2	0	low
28 camcer.CEL	1	0	1	5.67	0	70	30	2	2	0	high
45 cancer.CEL	1	0	1	5.00	1	0	0	2	1	0	high
48 cancer.CEL	1	1	1	4.00	0	0	0	3	3	1	high
58 cancer.CEL	1	1	1	4.75	0	70	15	3	3	1	low
59 cancer.CEL	1	1	1	3.42	1	50	40	3	1	0	high
62 cancer.CEL	0		0	1.33	1	0	0	3	3	1	low
64 cancer.CEL	0		0	1.75	1	0	0	3	2	0	high
65 cancer.CEL	1	1	1	5.00	0	80	0	3	3	1	low

Supplementary Table 3. Predicted risk groups and clinical data for survival analysis of 109 Taiwanese breast cancers

66 cancer.CEL	1	1	1	4.92	0	90	50	2	3	1	low
69 cancer.CEL	0		0	4.92	0	0	0	3	1	0	high
70 cancer.CEL	1	0	1	4.92	0	95	95	2	2	0	low
72 cancer.CEL	1	1	0	5.00	0	0	0	3	3	1	high
75 cancer.CEL	1	1	1	4.67	0	0	0	3	3	1	high
76 cancer.CEL	0		1	4.75	0	80	60	2	1	0	low
78 cancer2.CEL	1	1	1	4.83	0	0	0	3	1	0	high
90T.CEL	1	1	1	4.50	0	10	10	3	1	0	high
111T.CEL	1	1	1	4.17	0	95	15	2	1	0	high
112T.CEL	1	0	1	4.08	0	95	95	1	2	0	high
120T.CEL	1	1	1	0.08	1	0	0	3	2	0	high
128T.CEL	1	0	1	3.67	0	95	95	3	3	1	low
129T.CEL	1	0	1	3.67	0	95	60	2	3	1	low
133T.CEL	1	1	1	3.58	0	0	0	3	3	1	low
134T.CEL	1	1	1	3.08	0	0	0	3	3	1	high
135T.CEL	1	0	1	2.08	1	70	10	3	1	0	high
136T.CEL	1	0	1	3.17	0	95	95	2	1	0	high
140T.CEL	1	1	1	2.17	0	0	0	2	3	1	high
142T.CEL	1	1	1	1.25	0	0	0	3	3	1	low
151T.CEL	1	1	1	4.17	0	60	30	2	3	1	low
153T.CEL	1	1	1	1.75	0	0	0	2	3	1	high
154T.CEL	1	1	1	2.67	0	80	90	2	3	1	low
BH0312-3.CEL	1	0	0	4.58	0	95	60	2	3	1	low

BH0312-4.CEL	1	0	1	4.58	0	20	10	2	2	0	high
BH0312-6.CEL	0		0	4.58	0	0	0	3	3	1	low
BH0312-7.CEL	1	1	1	1.17	1	0	0	3	3	1	low
BH0312-8.CEL	1	1	1	4.25	0	75	75	3	1	0	high
BH0312-9.CEL	1	0	0	4.25	0	90	90	3	1	0	high
BH0312-10.CEL	1	0	1	4.17	0	80	80	2	2	0	high
BH0312-11.CEL	1	1	1	4.08	0	95	95	3	2	0	high
BH0312-12.CEL	1	0	1	3.83	0	40	10	3	3	1	low
BH0312-13.CEL	1	1	1	1.08	1	0	0	3	2	0	high
BH0344-2.CEL	0		0	4.50	0	95	40	2	1	0	high
BH0344-3.CEL	1	0	1	4.50	0	95	30	2	3	1	low
BH0344-4.CEL	1	0	1	3.42	1	15	0	2	2	0	high
BH0344-7.CEL	1	0	1	3.83	0	95	70	2	3	1	low
BH0344-9.CEL	1	0	1	2.83	0	95	95	2	2(1.02)	0	high
BH0344-10.CEL	1	0	1	2.58	0	95	0	2	2(0.82)	0	high
BH0354-1.CEL	1	0	1	4.58	0	90	0	3	2	0	low
BH0354-2.CEL	0		1	4.17	0	0	0	2	3	1	low
BH0354-3.CEL	1	1	1	2.17	1	95	15	3	1	0	high
BH0354-4.CEL	1	0	0	2.92	0	10	0	3	2(1.14)	0	high
BH0394-1.CEL	1	1	1	4.67	0	90	50	2	2	0	low
BH0394-2.CEL	1	1	1	4.17	0	0	0	2	3	1	low
BH0394-3.CEL	1	0	0	4.50	0	95	25	1	2	0	low
BH0394-4.CEL	1	0	1	4.50	0	95	10	2	1	0	low

BH0394-5.CEL	1	1	1	4.42	0	95	30	2	2	0	low
BH0394-6.CEL	1	0	1	4.33	0	95	10	3	2	0	low
BH0394-7.CEL	0		1	4.25	0	95	5	3	3	1	low
BH0394-8.CEL	1	0	0	3.00	0	95	30	2	2(1.1)	0	high
BH0394-9.CEL	1	0	1	2.92	0	90	40	1	1	0	low
BH0394-10.CEL	1	0	1	0.50	0	0	0	2	3	1	low
BH0396-1.CEL	1	0	0	4.67	0	50	60	2	0	0	high
BH0396-2.CEL	1	1	1	4.08	0	60	5	3	3	1	low
BH0396-3.CEL	1	0	1	4.25	0	95	50	2	2	0	low
BH0396-4.CEL	1	1	1	0.08	0	95	1	3	3	1	low
BH0396-5.CEL	1	1	1	3.25	0	80	5	3	2	0	high
BH0396-6.CEL	0		1	4.33	0	80	60	2	1	0	high
BH0396-7.CEL	1	0	1	2.42	0	95	30	2	0	0	high
BH0396-10.CEL	1	1	1	2.50	0	70	30	2	3	1	low
BH0430-2.CEL	1	1	1	0.50	0	0	0	3	3	1	low
BH0434-1.CEL	1	0	1	0.00	1	90	20	2	2(1.76)	0	low
BH0470-1.CEL	1	0	0	1.75	0	90	50	2	1	0	high
BH0470-2.CEL	1	1	1	1.75	0	0	0	3	3	1	high
BH0470-3.CEL	1	0	1	1.75	0	9	9	3	1	0	high
BH0470-5.CEL	1	0	1	1.50	0	90	30	2	3	1	low
BH0470-6.CEL	1	1	1	1.42	0	70	70	3	1	0	low
BH0478-3.CEL	1	0	1	1.50	0	90	90	2	1	0	low
BH0478-4.CEL	1	0	1	1.50	0	90	30	2	1	0	low

BH0478-5.CEL	1	0	1	1.25	0	90	90	2	2(1.06)	0	high
BH0478-6.CEL	1	1	1	1.17	0	0	0	3	1	0	high
BH0485-3.CEL	1	0	1	1.50	0	90	0	2	2(3.32)	1	low
BH0485-4.CEL	1	1	1	1.42	0	0	0	3	3	1	high
BH0485-5.CEL	1	0	1	1.42	0	90	10	2	1	0	low
BH0485-6.CEL	1	1	1	1.42	0	1	0	3	3	1	high
BH0485-7.CEL	1	0	0	1.42	0	90	3	1	1	0	low
BH0485-8.CEL	1	0	1	0.00	1	95	98	3	1	0	low
BH0485-9.CEL	1	1	1	1.25	0	0	0	3	3	1	high
BH0485-10.CEL	1	0	0	1.33	0	1	0	2	3	1	high
BH0505-3.CEL	1	0	1	1.00	0	95	60	2	1	0	low
BH0505-5.CEL	0		0	1.00	0	0	0	3	2(1.95)	0	high
BH0505-8.CEL	1	1	0	0.00	0	0	0	3	3	1	low
BH0505-9.CEL	1	1	1	1.67	0	20	0	3	1	0	low
BH0533-1.CEL	1	1	1	0.75	0	98	0	3	1	0	low
BH0533-2.CEL	1	0	0	1.58	0	90	60	2	2(2.21)	1	low
BH0533-3.CEL	0		1	1.50	0	1	0	2	3	1	high
BH0533-4.CEL	0		0	1.58	0	90	5	2	1	0	high
BH0533-5.CEL	1	1	1	0.83	0	60	5	3	3	1	low
Breast Cancer	1	1	1	4.33	0	0	0	2	3	1	high
Breast Cancer	1	0	1	4.25	0	95	40	2	2	0	high

Breast Cancer											
	1	0	1	4.00	0	0	0	2	3	1	high
121T.CEL											

.

Gene symbol list (from top to bottom) for Y-axis of Fig 3
Symbol
EHD3
SLC22A17
IGFBP2
C19orf25
STK16
ZDHHC16
HPS6
ZBTB9
NOP9
MUL1
HTRA2
GLTPD1
SCAMP2
FDFT1
RAI1
DNAL4
YWHAQ
TOR1B
FAM213B
KRT71
TMEM203
ATRN
DCP1B
ALG2
ENOPH1
KIAA1279
SLC25A38
CINP
TMEM25
DNAJC16
OGFOD3
TMEM242
S100A14
PRDX2
SLC17A6
TLR8-AS1

TKTL1 IL1RAP CPA4 NFE4 AGO3 DUSP22 CCDC17 CTRL LOC284009 PSORS1C3 AP000330.8 GAS6-AS1 PLAC8L1 GUCY1B2 PPIEL RP1-17K7.2 RP3-365O12.2 LINC00113 DKFZp667F0711 PRR26 CNTNAP3 LINC00639 LINC00973 LINC00485 LGSN FLJ37786 ALX1 ZNF876P NECAB2 KRT85 GK5 LINC00328 OR10D3 RNF213 FAHD2CP CYP1A2 HIST1H1T KCNK9

EMR3 GPR97 LINC00302 IL20RB SERPINB7 SLCO4A1 NWD2 ANGPTL4 PKD1L2 EIF1 LSMEM1 PPFIA4 MAGEA4 CACNA1B LOC101060391 RHBDL1 RRN3P2 HCG27 XRCC2 WDFY2 GPBP1L1 MARK3 GRB10 MYL6 GNRH1 BIN3-IT1 LINC00893 LINC00894 NOMO3 MDN1 ARHGEF10 RRN3P3 MKNK1 **KIAA0754** NRD1 UGP2 FAM185A PRO2852

GOLGA4 CFLAR DSERG1 LOC100129406 TMEM43 KATNBL1 LOC100507311 LOC100131541 PCSK7 TMEM63A ECHDC2 EIF3B SSBP1 ARF1 CLDN15 LINC00152 RALGAPA2 FAM13A-AS1 DOCK4 PRKAA1 LOC645513 LINC01125 UQCRC2 LOC100507281 CREB5 ASAP1-IT1 FLJ21369 MAEL NQO2 SCML1 SCML2